Niacin/laropiprant products to be suspended worldwide

The European Medicines Agency (EMA) has recommended that the marketing, supply, and authorisations of three identical niacin/laropiprant products—Tredaptive, Pelzont, and Trevaclyn—for the treatment of adults with dyslipidemia be suspended across the European Union
Source: Pharmacy Europe - Category: Drugs & Pharmacology Source Type: news